GSK - GlaxoSmithKline plc
NYSE
->
Healthcare
->
Drug Manufacturers—General
Brentford,
United Kingdom
Type: Equity
GSK price evolution
GSK
| (in millions $) | 5 Mar 2024 | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $5376.8 | $6639.2 | $6688.42 | |
| Short term investments | $521.91 | $469.9 | $496.7 | |
| Net receivables | $7662.61 | $7758 | $8874 | $6968.13 |
| Inventory | $5704.68 | $5498 | $5480 | $5668.29 |
| Total current assets | $19344.86 | $18644 | $21240 | $19896.6 |
| Long term investments | $41878.23 | $39362.29 | $41250.39 | |
| Property, plant & equipment | $9359.08 | $9957 | $9454 | $8906.58 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $61223.09 | $59005 | $60862 | $61146.99 |
| Current liabilities | ||||
| Accounts payable | $3856.73 | $15844 | $15582 | $13951 |
| Deferred revenue | ||||
| Short long term debt | $2918.74 | $4811.26 | $6088.89 | |
| Total current liabilities | $21859.98 | $21068 | $22390 | $22734.86 |
| Long term debt | $15776.58 | $15205 | $15993 | $15994 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $47374.35 | $45658 | $47729 | $48096.14 |
| Shareholders' equity | ||||
| Retained earnings | $7511.12 | $8548 | $8335 | $6599.98 |
| Other shareholder equity | ||||
| Total shareholder equity | $13848.73 | $13046.92 | $13050.85 | |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 8 Mar 2022 | 30 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $748 | $879 | $3307.6 | $6292 |
| Short term investments | $586.3 | $514.26 | $480 | |
| Net receivables | $7403 | $7458 | $5997.18 | $6862 |
| Inventory | $5498 | $5146 | $4412.43 | $5996 |
| Total current assets | $18644 | $20769 | $14248.26 | $20247 |
| Long term investments | $38801.39 | $46107.33 | $3496 | |
| Property, plant & equipment | $9957 | $9620 | $7578.12 | $11006 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $77276.25 | |||
| Total investments | ||||
| Total assets | $59005 | $60146 | $60355.59 | $80431 |
| Current liabilities | ||||
| Accounts payable | $3717 | $16263 | $3460.2 | $4357 |
| Deferred revenue | ||||
| Short long term debt | $3894.23 | $2747.56 | $2449 | |
| Total current liabilities | $21068 | $22810 | $18060.21 | $22148 |
| Long term debt | $15205 | $17035 | $15696.44 | $22538 |
| Total noncurrent liabilities | $48117.9 | |||
| Total debt | $37129.57 | |||
| Total liabilities | $45658 | $49548 | $48868.62 | $59623 |
| Shareholders' equity | ||||
| Retained earnings | $9368 | $5811 | $6061.27 | $7294 |
| Other shareholder equity | -$310 | -$373 | $1660 | $2666 |
| Total shareholder equity | $10443.08 | $11486.96 | $14587 | |
| (in millions $) | 5 Mar 2024 | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $8975.4 | $8052 | $8147 | |
| Cost of revenue | $2681.48 | |||
| Gross Profit | $6293.92 | $5719 | $5912 | |
| Operating activities | ||||
| Research & development | $2241.17 | |||
| Selling, general & administrative | $2961.02 | |||
| Total operating expenses | $7883.67 | $4150 | $3322 | |
| Operating income | $1091.73 | |||
| Income from continuing operations | ||||
| EBIT | $1355.36 | |||
| Income tax expense | $1.6 | -$19 | $257 | |
| Interest expense | -$194 | -$158 | ||
| Net income | ||||
| Net income | $484.53 | $350 | $1464 | |
| Income (for common shares) | $484.53 | |||
| (in millions $) | 31 Jan 2024 | 10 Mar 2023 | 31 Jan 2022 | 30 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $30328 | $28895.34 | $34099 | |
| Cost of revenue | $9414.34 | $10890 | ||
| Gross Profit | $21965 | $19481 | $23209 | |
| Operating activities | ||||
| Research & development | $5407.78 | $4678 | ||
| Selling, general & administrative | $8249.62 | $10503 | ||
| Total operating expenses | $13898 | $23071.73 | $25616 | |
| Operating income | $5823.61 | $8483 | ||
| Income from continuing operations | ||||
| EBIT | $6568.56 | $8483 | ||
| Income tax expense | $756 | $696.67 | $580 | |
| Interest expense | -$682 | -$860 | ||
| Net income | ||||
| Net income | $4928 | $14737.37 | $5749 | |
| Income (for common shares) | $14737.37 | $5749 | ||
| (in millions $) | 5 Mar 2024 | 31 Jan 2024 | 30 Oct 2023 | 26 Jul 2023 |
|---|---|---|---|---|
| Net income | $484.53 | $1670.05 | ||
| Operating activities | ||||
| Depreciation | -$1660.05 | $476.84 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $4851.75 | $1345.05 | ||
| Investing activities | ||||
| Capital expenditures | -$881.35 | -$560.1 | ||
| Investments | ||||
| Total cash flows from investing | $195.83 | -$1595 | -$1863 | -$999 |
| Financing activities | ||||
| Dividends paid | -$2247 | -$1679 | ||
| Sale and purchase of stock | ||||
| Net borrowings | $12796.62 | $14897.77 | ||
| Total cash flows from financing | -$3817.48 | -$5641 | -$2049 | $25.91 |
| Effect of exchange rate | -$99 | -$65 | ||
| Change in cash and equivalents | $5376.8 | -$567 | -$405 | $6688.42 |
| (in millions $) | 31 Jan 2024 | 10 Mar 2023 | 8 Mar 2022 | 30 Dec 2020 |
|---|---|---|---|---|
| Net income | $14737.37 | $3345.75 | $5749 | |
| Operating activities | ||||
| Depreciation | $2115.62 | $1813.65 | $2110 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $7827.87 | $6067.38 | $8441 | |
| Investing activities | ||||
| Capital expenditures | -$2224.99 | -$2236.35 | -$1226 | |
| Investments | $2853 | |||
| Total cash flows from investing | -$1595 | -$8643.77 | -$1355.85 | $2161 |
| Financing activities | ||||
| Dividends paid | -$2247 | -$3977 | ||
| Sale and purchase of stock | ||||
| Net borrowings | $12332.06 | $14622.13 | -$4234 | |
| Total cash flows from financing | -$5641 | $810.97 | -$5790.41 | -$10132 |
| Effect of exchange rate | -$99 | -$39 | ||
| Change in cash and equivalents | -$567 | $2996.47 | -$3314.78 | $431 |
News
|
12 Best Biotech Penny Stocks to Invest In
Insider Monkey via Yahoo Finance
24 Mar 2024
|
|
The Zacks Analyst Blog Highlights Booz Allen Hamilton, Molson Coors Beverage, Tyson Foods,...
Zacks via Yahoo Finance
14 Mar 2024
|
|
15 Best Drug Stocks To Invest In
Insider Monkey via Yahoo Finance
26 Nov 2023
|
|
The Zacks Analyst Blog Highlights Caterpillar, Equinor, GSK, Sysco and AmerisourceBergen
Zacks via Yahoo Finance
10 Jan 2023
|
|
Billionaire Steve Cohen’s Top 10 Dividend Stocks
Insider Monkey via Yahoo Finance
19 Nov 2022
|
|
12 Best Ethical Stocks To Buy Now
Insider Monkey via Yahoo Finance
11 Oct 2022
|
|
2 Dividend Stocks to Double Up On Right Now
Motley Fool
28 Sep 2022
|
|
GlaxoSmithKline (GSK) Gains As Market Dips: What You Should Know
Zacks via Yahoo Finance
18 Sep 2022
|
|
GlaxoSmithKline (GSK) Dips More Than Broader Markets: What You Should Know
Zacks via Yahoo Finance
10 Sep 2022
|
|
GSK Completes Demerger of Consumer Healthcare Business
Zacks via Yahoo Finance
19 Jul 2022
|
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | 98.60% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.88 |
| Quick ratio | 0.62 |